Hasumi International Research Foundation

The Hasumi International Research Foundation (HIRF) is a non-profit biotechnology organization dedicated to the development of advanced cancer immunotherapies. The foundation's primary focus is the Hasumi Immuno-Therapeutic Vaccine (HITV), a personalized dendritic cell-based therapy designed to target and eliminate cancer cells by stimulating the patient's own immune system. HIRF conducts extensive research into the synergy between therapeutic vaccines and other modalities like radiotherapy or chemotherapy. With facilities in Japan and the United States, the foundation collaborates with global institutions to advance clinical trials for various solid tumors. Their approach emphasizes active immunotherapy to improve survival rates and quality of life for patients with advanced or metastatic cancers.